Reta
Investigational triple GIP/GLP-1/GCG receptor agonist. Phase II data shows up to 24% mean weight loss at 48 weeks — among the highest reported for any metabolic compound to date.
Reta is an investigational triple receptor agonist developed by Eli Lilly that activates GIP, GLP-1, and GCG receptors simultaneously. The addition of GCG receptor agonism to the dual incretin mechanism of tirze is proposed to enhance energy expenditure through thermogenic effects, potentially explaining the superior weight loss data observed in Phase II trials.
A Phase II clinical trial reported 24% mean weight loss at 48 weeks with the highest dose tested — outcomes that exceed those of any currently approved metabolic agent and rival bariatric surgery results in some analyses. Phase III trials are underway to confirm efficacy and safety for an obesity indication.
Physician-practice off-label use exists but extrapolates significantly from Phase II data. The compound is not approved for any indication, and the optimal off-trial protocol remains undefined. Joseph describes 0.5–2 mg weekly as a starting range in practice contexts.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
Reta is not FDA-approved for any indication. GI side effect profile similar to GLP-1 class — nausea, vomiting, diarrhea. The GCG component adds potential cardiovascular considerations. Research use only. WADA-prohibited. All information for educational reference only.